Neola Medical AB (NEOLA) AI Stock Analysis

0 Followers

Neola Medical AB

(Nasdaq OMX AB:NEOLA)

Select Model

Rating:44Neutral

Price Target:SEK 0.48▼(-3.02% Downside)

Action:reiterated

Date:09/09/26

The score is primarily held back by very weak financial performance (near-zero revenue, ongoing losses, and continued cash burn). Technicals add additional caution given the price remains below key longer-term moving averages. Valuation provides little support due to negative earnings and no dividend yield data, while no earnings-call or corporate-event information was available to offset these risks.

Positive Factors

Debt-free balance sheetZero reported debt limits financial risk and avoids interest obligations, while substantial equity provides a buffer for continued product development. This gives Neola greater financial flexibility than a similarly loss-making company carrying material leverage, although losses can still erode that cushion over time.

Negative Factors

No meaningful revenue scaleRevenue remaining effectively zero over multiple years indicates that the company has not yet demonstrated commercial scale or recurring operating traction. Until product sales begin to grow, the business cannot validate demand through reported revenue or establish a self-sustaining commercial model.

Neola Medical AB (NEOLA) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 53.47M
Dividend Yield: ―
Average Volume (3M): 111.86K
Price to Earnings (P/E): -3.0
Beta (1Y): -0.40
Revenue Growth: ―
EPS Growth: -13.49%
Country: Sweden
Employees: 9
Sector: General
Sector Strength: 55
Industry: Medical - Devices

Neola Medical AB Business Overview & Revenue Model

Company Description

Neola Medical AB (publ) specializes in developing advanced medical devices for the continuous pulmonary assessment of premature babies. At the core of its offerings is NEOLA, a sophisticated medical instrument critical for neonatal intensive care. Th...

How the Company Makes Money

Neola Medical AB’s revenue model is primarily tied to commercializing its medical device(s) for neonatal monitoring, which would typically generate income through sales of devices to hospitals/clinics and potentially recurring revenue from associated...

Neola Medical AB Financial Statement Overview

Summary

Overall financials are weak: revenue is effectively zero across 2022–2025 with persistent net losses (~SEK 11.0M loss in 2025). Cash flow remains negative with ongoing operating cash burn (~-SEK 12.0M in 2025). The main offsetting positive is a strong balance sheet with zero reported debt and meaningful equity (~SEK 75.8M in 2025), reducing near-term solvency risk.

Income Statement

18Very Negative

Balance Sheet

68Positive

Cash Flow

32Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0	0	0	0	0	625.00K
Gross Profit	3.50M	-1.39M	-1.53M	-1.43M	-571.00K	-7.36M
EBITDA	-7.34M	-9.75M	-8.54M	-7.42M	-9.32M	-6.64M
Net Income	-8.38M	-11.02M	-10.06M	-9.01M	-10.35M	-6.65M
Balance Sheet
Total Assets	78.80M	78.80M	73.61M	86.02M	75.33M	43.83M
Cash, Cash Equivalents and Short-Term Investments	16.12M	16.12M	19.55M	21.58M	40.09M	22.94M
Total Debt	0	0	0	0	0	0
Total Liabilities	3.00M	3.00M	4.65M	6.99M	7.84M	3.19M
Stockholders Equity	75.80M	75.80M	68.96M	79.03M	67.48M	40.63M
Cash Flow
Free Cash Flow	-9.50M	-21.25M	-10.84M	-18.85M	-20.05M	-17.45M
Operating Cash Flow	-8.90M	-11.95M	-10.84M	-6.54M	-8.50M	-6.93M
Investing Cash Flow	-7.57M	-9.34M	-11.18M	-12.30M	-11.56M	-10.52M
Financing Cash Flow	-68.00K	17.86M	20.00M	336.00K	37.20M	23.74M

Neola Medical AB Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.50

Price Trends

50DMA0.51Negative

100DMA0.58Negative

200DMA0.74Negative

Market Momentum

MACD-0.00Positive

RSI49.89Neutral

STOCH28.28Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:NEOLA, the sentiment is Neutral. The current price of 0.50 is below the 20-day moving average (MA) of 0.51, below the 50-day MA of 0.51, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.00 indicates Positive momentum. The RSI at 49.89 is Neutral, neither overbought nor oversold. The STOCH value of 28.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:NEOLA.

Neola Medical AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

SE:NEOLA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SE:SEZI	55Neutral	SEK 588.77M	-5.80	-35.44%	―	18.56%	28.11%
SE:BACTI.B	53Neutral	SEK 539.68M	80.83	1.93%	―	-0.51%	―
SE:BRAIN	53Neutral	SEK 443.05M	-9.65	-22.23%	―	0.04%	34.45%
SE:SEDANA	49Neutral	SEK 910.92M	-25.91	-3.88%	―	0.42%	15.03%
SE:NEOLA	44Neutral	SEK 53.47M	-3.04	―	―	―	-13.49%
SE:ACARIX	42Neutral	SEK 200.71M	-5.36	-96.06%	―	40.61%	32.63%

* General Sector Average

Performance Comparison

SE:NEOLA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:NEOLA	Neola Medical AB	0.50	-0.88	-63.82%
SE:SEZI	Senzime AB	3.60	-1.52	-29.65%
SE:BACTI.B	Bactiguard Holding AB	14.55	-1.65	-10.19%
SE:ACARIX	Acarix AB	0.17	-0.10	-37.04%
SE:BRAIN	BrainCool AB	1.12	0.57	104.00%
SE:SEDANA	Sedana Medical AB	9.00	-0.65	-6.74%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 09, 2026

Neola Medical AB AI Stock Analysis